Bone Profile Blood Test Explained: Calcium, Phosphate, ALP, and Vitamin D

A bone profile — also called a bone chemistry panel or calcium and bone profile — is a group of blood tests that together give an overview of bone metabolism and the mineral systems that regulate it. Bones are dynamic tissues constantly being built and broken down, and this process depends on precise regulation of calcium, phosphate, parathyroid hormone (PTH), and vitamin D. When any of these are disrupted, both bone health and broader physiological systems can be affected. The bone profile is ordered to investigate symptoms such as bone pain or fractures, to monitor patients with known metabolic bone disease, and to screen for conditions affecting calcium regulation.

Calcium

Calcium is the most abundant mineral in the body and is essential for bone structure, nerve transmission, muscle contraction, and coagulation. Approximately 99% of body calcium is stored in bone; the remaining 1% circulates in blood. Of the circulating calcium, about 40% is bound to albumin (biologically inactive), 10% forms complexes with ions such as phosphate and citrate (inactive), and 50% is free ionised calcium (the biologically active form). Typical reference range for total calcium: 2.2–2.6 mmol/L. Because bound calcium depends on albumin concentration, low albumin (e.g., in malnutrition or liver disease) will cause a low total calcium even if physiologically active ionised calcium is normal. For this reason, laboratories report an adjusted (corrected) calcium that compensates for the albumin level. Ionised calcium can also be measured directly on a blood gas analyser.

Hypercalcaemia (high calcium) most commonly results from primary hyperparathyroidism (excess PTH secretion, usually from a parathyroid adenoma) or malignancy (bone metastases or PTH-related peptide secretion by tumours). Other causes include vitamin D toxicity, sarcoidosis, and immobilisation. Hypocalcaemia (low calcium) most commonly results from vitamin D deficiency or hypoparathyroidism; it can also occur in chronic kidney disease (impaired vitamin D activation) and hypomagnesaemia.

Phosphate

Phosphate works with calcium in bone mineralisation and is also essential for cellular energy metabolism (ATP) and acid-base regulation. Like calcium, phosphate is regulated by PTH, vitamin D, and fibroblast growth factor 23 (FGF-23). Typical reference range: 0.8–1.5 mmol/L. Hyperphosphataemia (high phosphate) is most commonly seen in chronic kidney disease (impaired excretion) and is a marker of CKD progression. Hypophosphataemia (low phosphate) occurs in malnutrition, malabsorption, vitamin D deficiency, and primary hyperparathyroidism (PTH promotes phosphate excretion). Severe hypophosphataemia can cause muscle weakness and impaired bone mineralisation (osteomalacia).

Alkaline Phosphatase (ALP)

Alkaline phosphatase is an enzyme found in several tissues including bone, liver, bile ducts, kidney, and placenta. In a bone profile, ALP is a marker of osteoblast activity — bone-building cells release ALP when actively synthesising new bone matrix. Elevated ALP in a bone profile context can indicate increased bone turnover in Paget’s disease of bone (focal excessive bone remodelling), bone metastases, osteomalacia or rickets (softened bone due to vitamin D deficiency), healing fractures, and primary hyperparathyroidism. However, ALP is also elevated in liver and biliary disease (cholestasis, hepatitis). When ALP is raised, differentiating the source (bone vs. liver) requires clinical context, GGT measurement (GGT is elevated in liver disease but not bone disease), or bone-specific ALP isoenzyme testing. Typical reference range: 30–130 U/L (age- and sex-dependent; higher in children and adolescents due to normal bone growth).

Vitamin D (25-Hydroxyvitamin D)

Vitamin D is a fat-soluble vitamin and hormone precursor. It is obtained from sun exposure (skin synthesis from cholesterol) and dietary sources (oily fish, fortified foods, supplements). The liver converts vitamin D to 25-hydroxyvitamin D (25-OHD, calcidiol) — the main circulating and storage form, measured in blood tests. The kidneys then convert 25-OHD to the biologically active form, 1,25-dihydroxyvitamin D (calcitriol), which promotes calcium and phosphate absorption from the gut. Vitamin D deficiency is extremely common worldwide and causes rickets in children (failure of bone mineralisation during growth) and osteomalacia in adults (softening of existing bone). It is also associated with osteoporosis, muscle weakness, and impaired immune function. Typical reference ranges: deficiency below 25 nmol/L; insufficiency 25–50 nmol/L; sufficient above 50 nmol/L (UK guidance from NICE).

Common Bone Conditions Assessed by the Bone Profile

Osteoporosis is characterised by reduced bone density and increased fracture risk; bone profile tests are often normal in osteoporosis (DEXA scanning, not blood tests, is used to diagnose it), but they are ordered to exclude secondary causes. Osteomalacia and rickets result from inadequate mineralisation due to vitamin D or phosphate deficiency — bone profile typically shows low/normal calcium, low phosphate, elevated ALP, low vitamin D. Primary hyperparathyroidism causes high calcium, low phosphate, elevated ALP, and high PTH. Paget’s disease causes markedly elevated ALP with normal calcium and phosphate. Bone metastases may cause elevated calcium (hypercalcaemia of malignancy) and elevated ALP.

References

1. National Library of Medicine. Calcium Blood Test. MedlinePlus. https://medlineplus.gov/lab-tests/calcium-blood-test/
2. NHS. Vitamin D. https://www.nhs.uk/conditions/vitamins-and-minerals/vitamin-d/
3. NICE. Vitamin D: supplement use in specific population groups. Public Health Guideline PH56. 2014.
4. NICE Guideline NG187. Osteoporosis: assessing the risk of fragility fracture. 2012 (updated 2017).
5. Kanis JA et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019;30(1):3–44.